Skip to main content

Table 4 Incremental Cost-effectiveness Ratios

From: The cost-effectiveness of screening tools used in the diagnosis of fetal alcohol spectrum disorder: a modelled analysis

Strategy

Cost

Effectiveness

Δ Cost

Δ Effectiveness

ICER

No screening

$7,007,542.41

709.34

   

Meconium Testing

$6,918,356.37

671.54

-$89,186.04

−37.80

$2359.15

No screening

$4,366,538.94

778.23

   

The NST

$4,182,643.95

701.28

-$183,894.98

−76.95

$2389.86

  1. Cost and number of years with an FASD diagnosis in Table 4 reflect per 100 individuals screened
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us